Loading...
•
Sep 30, 2020
Ardelyx Q3 2020 Earnings Report
Reported revenue of $2.7 million and net loss of $18.1 million.
Key Takeaways
Ardelyx reported Q3 2020 financial results, with the FDA accepting the NDA for tenapanor and a PDUFA goal date set for April 29, 2021. The company maintains a strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments.
FDA accepted the New Drug Application (NDA) for tenapanor with a PDUFA goal date of April 29, 2021.
Presented new clinical data supporting the clinical safety and efficacy of tenapanor at ASN Kidney Week 2020.
Cash, cash equivalents and short-term investments totaled $185.5 million as of September 30, 2020.
Net loss for the quarter ended September 30, 2020 was $18.1 million, or ($0.20) per common share.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...